Travere Therapeutics (NASDAQ:TVTX) Chief Financial Officer Christopher R. Cline recorded multiple insider transactions in mid-April 2026, selling company common stock in trades that totaled $348,974. The disclosures, filed on a Form 4 with the Securities and Exchange Commission, itemize sales executed over three consecutive days and detail an associated grant of shares that vested the same week.
The Form 4 indicates Cline sold 65 shares on April 13, 2026 at $28.85 per share. On April 14, 2026 he sold 9 shares at $41.07 and 7,239 shares at $41.9288 per share. On April 15, 2026 he sold an additional 1,014 shares at $42.61 per share. Collectively, those transactions amount to $348,974 in gross proceeds with trade prices spanning from $28.85 to $42.61.
Also on April 13, 2026, Cline acquired 14,000 shares of common stock at a $0 per-share cost. That acquisition resulted from the vesting of performance restricted stock units (PSUs) that vested upon the issuer confirming that the U.S. Food and Drug Administration had granted approval of FILSPARI (sparsentan) for focal segmental glomerulosclerosis (FSGS).
Following the April transactions and the PSU vesting, Cline is reported to directly own 116,899 shares of Travere Therapeutics.
Market context and financial signals
The insider activity comes while Travere's share price sits close to its 52-week high of $43.31, a level the company’s stock has reached as it posted a 181% return over the previous 12 months. According to InvestingPro data noted in the filing materials, Travere registered a loss of $0.56 per share over the last twelve months, while analysts are projecting a shift to profitability with forecasted earnings of $1.84 per share for 2026. Investors are pointed to an available Pro Research Report on TVTX and more than 1,400 other U.S. equities for in-depth analysis.
Regulatory milestone and analyst reaction
In related corporate news, Travere has received full FDA approval for its drug Filspari to treat focal segmental glomerulosclerosis in adult and pediatric patients aged 8 years and older. The approval designates Filspari as the first and only FDA-approved treatment specifically for FSGS, according to the company disclosures.
Following that regulatory milestone, several analyst firms adjusted their views and price targets. Guggenheim raised its price target to $54 while keeping a Buy rating. Stifel increased its target to $43 and maintained a Hold rating, and noted expectations for a rapid launch. Cantor Fitzgerald reiterated an Overweight rating, citing the broad label approval across FSGS patient categories. H.C. Wainwright also reiterated a Buy rating and set a $47 price target, highlighting the significance of the regulatory approval.
These filings and analyst updates provide investors with a snapshot of insider liquidity activity, corporate milestones, and shifting market expectations as Travere prepares to commercialize its newly approved therapy.